Latest Breaking News On - Cell therapeutics - Page 12 : comparemela.com

HC Wainwright Reiterates Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $7.00 price objective on the stock. Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $6.00 price target on shares of […]

United statesDonm baileyDefender capitalSecurities exchange commissionBarclays plcAmerican international group incRaffles associatesFort sheridan advisorsCantor fitzgeraldLineage cell therapeutics incLineage cell therapeutics company profileLineage cell therapeuticsGet free reportCell therapeuticsDirector broadwood partnersExchange commission

Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury

The DOSED Clinical Study Will Evaluate a Novel Delivery Device in Subacute and Chronic Spinal Cord Injury Patients .

United statesBrianm culleyCalifornia institute for regenerative medicine under propositionInternational spinal cord injury pain questionnaireCalifornia institute for regenerative medicineRoche groupDrug administrationExchange commissionCalifornia stem cell agencyInternational spinal cord injury pain basic dataLineage cell therapeutics incLineage cell therapeuticsInvestigational new drugOligodendrocyte progenitor cellsSpinal cord injuryNovel device

Lineage Cell Therapeutics, Inc (NYSEAMERICAN:LCTX) Director Don M Bailey Buys 96,155 Shares

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Free Report) Director Don M. Bailey acquired 96,155 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was purchased at an average price of $1.04 per share, with a total value of $100,001.20. Following the transaction, the director now owns 158,801 shares […]

United statesDonm baileyLineage cell therapeutics incRathbones groupDeutsche bankSecurities exchange commissionLineage cell therapeutics company profileSg americas securitiesVanguard group incCantor fitzgeraldNorthern trust corpLineage cell therapeuticsGet free reportDirector donExchange commissionCell therapeutics

Broadwood Partners, L P Purchases 6,730,770 Shares of Lineage Cell Therapeutics, Inc (NYSEAMERICAN:LCTX) Stock

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Free Report) Director Broadwood Partners, L.P. bought 6,730,770 shares of Lineage Cell Therapeutics stock in a transaction on Tuesday, February 6th. The stock was acquired at an average price of $1.04 per share, for a total transaction of $7,000,000.80. Following the purchase, the director now owns 41,666,255 shares […]

United statesCantor fitzgeraldBlackrock incLineage cell therapeutics incVanguard group incGeode capital managementDefender capitalLineage cell therapeuticsGet free reportDirector broadwood partnersCell therapeuticsCapital managementState street corpStreet corpLineage cell therapeutics dailyNyseamerican lctx

Lineage Cell Therapeutics Announces Closing of $14 0 Million Registered Direct Offering

Lineage Cell Therapeutics Announces Closing of $14 0 Million Registered Direct Offering
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNeal bradsherBrianm culleyDonm baileyDavid schullLineage cell therapeutics incRoche groupExchange commissionCell therapeuticsLineage cell therapeuticsAnnual reportMedia relations